Emmaus Life Sciences Sickle Cell Treatment Receives Positive Opinion on Pediatric Investigation Plan from European Medicines Agency
Emmaus Life Sciences announced today that the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the company's pediatric investigation plan (PIP) for its treatment of sickle cell disease. The decision allows Emmaus to proceed with the submission of a Marketing Authorization Application (MAA).
“The approval of our PIP represents a significant step forward in our efforts to bring this treatment to market in the European Union (EU),” said Yutaka Niihara, MD, MPH, Chairman and Chief Executive Officer of Emmaus Life Sciences, “We look forward to submitting our MAA in the near term and hope to provide sickle cell patients in the EU with a new treatment option once we complete the regulatory process.”
The EMA requires companies seeking to register new medicines to agree with the PDCO on a PIP that outlines a clinical development program for studying the investigational product in the pediatric population. An accepted PIP is required before a company can file an MAA for a new drug in the EU.
On July 7, 2017, the United States (U.S.) Food and Drug Administration approved Endari™ (L-glutamine oral powder), for its use in the U.S.
Emmaus has obtained both Orphan Drug designation in the U.S. and Orphan Medicinal Product designation in the E.U.
About Sickle Cell Disease
Sickle Cell Disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fibrous, causing red blood cells to become rigid and change form so that they appear sickle shaped instead of soft and rounded. Patients with Sickle Cell Disease suffer from debilitating episodes of sickle cell crises, which occur when the rigid, adhesive and inflexible red blood cells occlude blood vessels. Sickle cell crises cause excruciating pain as a result of insufficient oxygen being delivered to tissue, referred to as tissue ischemia, and inflammation. These events may lead to a variety of other adverse outcomes such as acute chest syndrome that requires hospitalization. Sickle Cell Disease is an orphan disease, affecting approximately 100,000 patients in the U.S. and millions worldwide with significant unmet medical needs.
Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.
Important Safety Information
The most common adverse reactions (incidence >10%) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain.
Adverse reactions leading to treatment discontinuation included 1 case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.
The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than 5 years of age has not been established.
For more information, please see full Prescribing Information of Endari at www.ENDARIrx.com/Repository/Prescribing%20information.pdf
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is engaged in the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The company's research on sickle cell disease was initiated by Yutaka Niihara, MD, MPH, Chairman and CEO of Emmaus, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. For more information, please visit www.emmauslifesciences.com.
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and potential commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Additional risks and uncertainties are described in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
for Emmaus Life Sciences
Lori Teranishi, 510-290-6160
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
BIOCAD: Interleukin-17 Inhibitor Shows High Efficacy After One Year of Therapy in Psoriasis Patients26.4.2018 12:08 | Tiedote
In March 2018, BIOCAD analyzed results from its Phase II study in which the original Russian IL-17 inhibitor proved highly effective in long-term therapy in patients with severe psoriasis. The drug also showed great results in the treatment of ankylosing spondylitis. BCD-085 is an original monoclonal antibody drug blocking interleukin-17, a cytokine playing a key role in developing and maintaining various autoimmune and immunoinflammatory diseases. The majority of psoriasis patients have serious psychological problems due to social isolation, while patients with ankylosing spondylitis may rapidly become disabled if diagnosed late or treated inappropriately. Both diseases are a serious medical and social challenge, especially because they often affect young people of working age (22 to 35 years old). The European market of IL-17 inhibitors is over $700 million and it’s going to grow to $1 677 million within next 5 years. BIOCAD expects to occupy an essential share of this perspective ma
Ecole hôtelière de Lausanne (EHL) Wins Best Employer Ranking26.4.2018 11:17 | Tiedote
Ecole hôtelière de Lausanne (EHL) wins the title of Best Employer in French-speaking Switzerland in the category of medium-sized companies in the annual ranking of the magazine Bilan published this week. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426005645/en/ Ecole hôtelière de Lausanne (EHL) Offering a dynamic and pleasant work environment on the campus north of Lausanne, the 464 employees of 33 nationalities benefit, among other things, from home-office opportunities, seven weeks of vacation, access to sport facilities and up to three free meals a day. Reacting to the announcement, CEO of the EHL Group, Mr Rochat said "the quality of the work environment is one of the priorities set for the EHL management. It is important for us to be able to attract and retain the best talent to continue to provide the best training to our students, and maintain our leadership position in teaching Hospitality Management. We work o
Ripple Grows Its Global Payments Network With Five New xVia Customers26.4.2018 11:00 | Tiedote
Ripple, the enterprise blockchain solution for global payments, is announcing that five new customers across Europe and Asia - FairFX (U.K.), RationalFX (U.K.), Exchange4Free (U.K.), UniPAY (Georgia), and MoneyMatch (Malaysia) - will use xVia to power frictionless payments over RippleNet. Requiring just one standard integration, xVia is an API solution enabling payment originators - those sending a payment on behalf of a customer, but not actually processing and paying it out - to access and reap the benefits of RippleNet. This includes faster entry into new markets, lower operational costs, increased speed and end-to-end visibility over a payment’s journey. “By tapping our global network with xVia, our customers now access new markets quicker and cost efficiently,” said Asheesh Birla, senior vice president of product at Ripple. “All of these customers run into the same problem: building bespoke connections to banks and networks all over the world. It’s expensive and time consuming. xV
Alibaba Cloud Receives MySQL Corporate Contributor Award26.4.2018 11:00 | Tiedote
Alibaba Cloud, the cloud computing arm of Alibaba Group, has won the 2018 MySQL Community Awards: Corporate Contributor, which recognizes its contribution to the MySQL ecosystem, the world’s most popular open source database. The award, presented earlier this week at the Percona Live conference held in Santa Clara, California, is another accolade for the global cloud services provider. The award recognized Alibaba Cloud’s contributions to the open source communities and its efforts to empower developers around the world in recent years. Today, more than one hundred thousand MySQL instances are running on ApsaraDB for RDS, Alibaba Cloud’s relational database services. This is the second time Alibaba has received the coveted award from the MySQL community. In 2015, Alibaba Group became the first Asian company to be named a WebScaleSQL Contributor, alongside Facebook, Google, Twitter and LinkedIn. The award is a ‘from-the-community, by-the-community, and for-the-community’ initiative and
Bentley Systems Acquires Plaxis, and Complementary SoilVision, to Integrate Geotechnical Engineering within Digital Workflows for Infrastructure Projects26.4.2018 09:00 | Tiedote
Bentley Systems, Incorporated, a leading global provider of comprehensive software solutions for advancing infrastructure, today announced the acquisition of Plaxis, the leading provider of geotechnical software, based in Delft, Netherlands, and the agreement to acquire soil engineering software provider SoilVision, based in Saskatchewan, Canada. The acquisitions, with Bentley’s market-leading borehole reporting and data management software gINT, serve to make Bentley a complete source for geotechnical professionals “going digital.” Finally, BIM advancements can be extended to the essential subsurface engineering of every infrastructure project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180425006935/en/ PLAXIS 3D performs three-dimensional analysis of deformation, soil-structure interaction, and stability in geotechnical engineering and rock mechanics. Projects necessarily begin with geotechnical surveys and sampling, c
Waterstones announces Change of Ownership26.4.2018 09:00 | Tiedote
Waterstones, the leading UK bookseller, announces today that it has entered into a binding agreement to be acquired and financed by funds managed by Elliott Advisors (UK) Ltd (“Elliott”). Waterstones operates a chain of 283 bookshops located across the UK and in Ireland, The Netherlands and Belgium. It had sales of over £400 million in the year to the end of April 2017. Lynwood Investments, controlling shareholder of Waterstones since 2011, will retain a minority stake. Founded in 1977, Elliott is one of the oldest and largest private investment organisations globally, with funds under management of approximately $35 billion. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott has an active and growing presence in private equity, investing globally with notable past and current investments including ASG Technologies, Charter Court Financial Services, Dell Software, Gigamon, Game Digital
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme